Correction of facial lipoatrophy with a biodegradable material in HIV-infected patients;Correction par produit biodégradable des lipoatrophies faciales des malades infectés par le VIH

Annales de Dermatologie et de Venereologie

Volumn 132, Issue 6-7 I, 2005, Pages 521-524

  Carbonnel, E ^a   Claudy, A ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

POLYACRYLAMIDE;

ARTICLE; BIODEGRADABLE IMPLANT; CONTROLLED STUDY; ECHOGRAPHY; FACE SURGERY; FACILA LIPOATROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOATROPHY; MAJOR CLINICAL STUDY; PROSPECTIVE STUDY; QUALITY OF LIFE;

EID: 22344447249     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0151-9638(05)79331-5     Document Type: Article

References (12)

1. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitor. AIDS 1998;12: F51-F58.
2. Delfraissy JF. Prise en charge des personnes infectées par le VIH. Rapport 2002. Médecine-Sciences Flammarion, 1 vol., p.118.
3. Hirsh HH, Battegay M. Lipodystrophy syndrome by HAART in HIV-1-infected patients: manifestation, mechanism and management. Infection 2002;30:293-8.
4. Martinez E, Mocroft A, García-Viejo MA, Pérez-Cuevas JB, Blanco JL, Mallolas J, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001;357: 592-8.
5. Savès M, Raffi F, Capeau J, Rozenbaum W, Ragnaud JM, Perronne C, et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis 2002;34:1396-405.
6. Carr A, Hudson J, Chuah J, Mallal S, Law M, Hoy J, et al. HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. AIDS 2001;15:1811-22.
7. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA 2000;284:472-7.
8. Torres RA, Unger KW, Cadman JA, Kassous JY. Recombinant human growth hormone improves truncal adiposity and 'buffalo humps' in HIV-positive patients on HAART. AIDS 1999;13:2479-81.
9. Moe KS, Weisman RA. Resorbable fixation in facial plastic and head and neck reconstructive surgery: an initial report on polylactic acid implants. Laryngoscope 2001;111:1697-1701.
10. Valantin MA, Aubron-Olivier C, Ghosn J, Laglenne E, Pauchard M, Schoen H, et al. Polylactic acid implants (New-Fill®) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS 2003;17:2471-7.
11. McCollister DD, Hake CL, Sadek CL, Rowe VK. Toxicologic investigation of polyacylamide. Toxicol Applied Pharmacol 1965;7:639-51.
12. King DJ, Noss RR. Toxicity of polyacrylamide monomer. Rev Environ Health 1989;8:3-16.